Prime Medicine PRME Unrealized gains (losses) on available-for-sale securities
Unrealized gains (losses) on available-for-sale securities at other companies
Other financials
Where this comes from
Reported directly by Prime Medicine in its filing.
Tagged under the XBRL concept us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax.
The official record: Prime Medicine’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Prime Medicine's unrealized gains (losses) on available-for-sale securities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Prime Medicine's unrealized gains (losses) on available-for-sale securities?
- Prime Medicine (PRME) reported unrealized gains (losses) on available-for-sale securities of -$83K in Q1 2026.
- How has Prime Medicine's unrealized gains (losses) on available-for-sale securities changed year-over-year?
- Prime Medicine's unrealized gains (losses) on available-for-sale securities decreased by 418.8% year-over-year, from -$16K to -$83K.
- What is the long-term trend for Prime Medicine's unrealized gains (losses) on available-for-sale securities?
- Over 2 years (2021 to 2025), Prime Medicine's unrealized gains (losses) on available-for-sale securities has grown at a 73.2% compound annual growth rate (CAGR), from -$27K to $81K.
- What does unrealized gains (losses) on available-for-sale securities mean?
- This metric represents the change in the fair value of available-for-sale debt or equity securities that is recognized in other comprehensive income rather than net income. It reflects unrealized gains or losses that are not yet realized through a sale but are required to be reported as part of the company's broader financial position. This provides transparency into the market-driven volatility of the company's investment portfolio.